ATE440087T1 - 2,4-diaminopyrimidinderivate, die sich als inhibitoren von pkc-theta eignen - Google Patents

2,4-diaminopyrimidinderivate, die sich als inhibitoren von pkc-theta eignen

Info

Publication number
ATE440087T1
ATE440087T1 AT04705675T AT04705675T ATE440087T1 AT E440087 T1 ATE440087 T1 AT E440087T1 AT 04705675 T AT04705675 T AT 04705675T AT 04705675 T AT04705675 T AT 04705675T AT E440087 T1 ATE440087 T1 AT E440087T1
Authority
AT
Austria
Prior art keywords
pkc
theta
inhibitors
compounds
diaminopyrimidene
Prior art date
Application number
AT04705675T
Other languages
English (en)
Inventor
Mario Cardozo
Derek Cogan
Charles Cywin
Georg Dahmann
Darren Disalvo
John Ginn
Anthony Prokopowicz
Denice SPERO
Erick Young
Original Assignee
Boehringer Ingelheim Pharma
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Boehringer Ingelheim Pharma filed Critical Boehringer Ingelheim Pharma
Application granted granted Critical
Publication of ATE440087T1 publication Critical patent/ATE440087T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
    • C07D239/48—Two nitrogen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • H—ELECTRICITY
    • H10—SEMICONDUCTOR DEVICES; ELECTRIC SOLID-STATE DEVICES NOT OTHERWISE PROVIDED FOR
    • H10K—ORGANIC ELECTRIC SOLID-STATE DEVICES
    • H10K85/00—Organic materials used in the body or electrodes of devices covered by this subclass
    • H10K85/30—Coordination compounds
    • H10K85/351—Metal complexes comprising lanthanides or actinides, e.g. comprising europium

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Immunology (AREA)
  • Diabetes (AREA)
  • Dermatology (AREA)
  • Materials Engineering (AREA)
  • Rheumatology (AREA)
  • Inorganic Chemistry (AREA)
  • Transplantation (AREA)
  • Endocrinology (AREA)
  • Pain & Pain Management (AREA)
  • Neurology (AREA)
  • Pulmonology (AREA)
  • Biomedical Technology (AREA)
  • Emergency Medicine (AREA)
  • Neurosurgery (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
AT04705675T 2003-01-30 2004-01-27 2,4-diaminopyrimidinderivate, die sich als inhibitoren von pkc-theta eignen ATE440087T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US44370003P 2003-01-30 2003-01-30
PCT/US2004/002240 WO2004067516A1 (en) 2003-01-30 2004-01-27 2,4-diaminopyrimidine derivatives useful as inhibitors of pkc-theta

Publications (1)

Publication Number Publication Date
ATE440087T1 true ATE440087T1 (de) 2009-09-15

Family

ID=32825361

Family Applications (1)

Application Number Title Priority Date Filing Date
AT04705675T ATE440087T1 (de) 2003-01-30 2004-01-27 2,4-diaminopyrimidinderivate, die sich als inhibitoren von pkc-theta eignen

Country Status (7)

Country Link
US (2) US20040242613A1 (de)
EP (1) EP1590334B1 (de)
JP (1) JP2006515014A (de)
AT (1) ATE440087T1 (de)
CA (1) CA2514612A1 (de)
DE (1) DE602004022633D1 (de)
WO (1) WO2004067516A1 (de)

Families Citing this family (62)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP4460292B2 (ja) 2001-10-17 2010-05-12 ベーリンガー インゲルハイム ファルマ ゲゼルシャフト ミット ベシュレンクテル ハフツング ウント コンパニー コマンディトゲゼルシャフト ピリミジン誘導体、これらの化合物を含む医薬組成物、その使用及びその調製方法
TWI329105B (en) 2002-02-01 2010-08-21 Rigel Pharmaceuticals Inc 2,4-pyrimidinediamine compounds and their uses
JP4324480B2 (ja) * 2002-03-26 2009-09-02 ベーリンガー インゲルハイム ファーマシューティカルズ インコーポレイテッド グルココルチコイドミメティクス、その製法、医薬組成物、及び使用
GB0215293D0 (en) 2002-07-03 2002-08-14 Rega Foundation Viral inhibitors
NZ538932A (en) * 2002-08-29 2007-04-27 Boehringer Ingelheim Pharma 3-(sulfonamidoethyl)-indole derivatives for use as glucocorticoid mimetics in the treatment of inflammatory, allergic and proliferative disease
EP1590334B1 (de) 2003-01-30 2009-08-19 Boehringer Ingelheim Pharmaceuticals Inc. 2,4-diaminopyrimidinderivate, die sich als inhibitoren von pkc-theta eignen
ES2421139T3 (es) 2003-07-30 2013-08-29 Rigel Pharmaceuticals, Inc. Compuestos de 2,4-pirimidindiamina para su uso en el tratamiento o la prevención de enfermedades autoinmunitarias
UY28526A1 (es) * 2003-09-24 2005-04-29 Boehringer Ingelheim Pharma Miméticos de glucocorticoides, métodos de preparación composiciones farmacéuticas y usos de los mismos
US7125996B2 (en) * 2003-10-03 2006-10-24 Boehringer Ingelheim Pharmaceuticals, Inc. Fluorescent probes for use in protein kinase inhibitor binding assay
US7572914B2 (en) 2003-12-19 2009-08-11 Takeda Pharmaceutical Company Limited Kinase inhibitors
DK2161273T3 (en) * 2003-12-22 2015-07-20 Leuven K U Res & Dev Imidazo [4,5-C] pyridine compounds and methods for antiviral therapy
TW200533357A (en) 2004-01-08 2005-10-16 Millennium Pharm Inc 2-(amino-substituted)-4-aryl pyrimidines and related compounds useful for treating inflammatory diseases
US7582631B2 (en) 2004-01-14 2009-09-01 Amgen Inc. Substituted heterocyclic compounds and methods of use
US7795272B2 (en) * 2004-03-13 2010-09-14 Boehringer Ingelheim Pharmaceutical, Inc. Glucocorticoid mimetics, methods of making them, pharmaceutical compositions and uses thereof
WO2005095357A2 (en) * 2004-03-30 2005-10-13 Taisho Pharmaceutical Co., Ltd. Pyrimidine derivatives and methods of treatment related to the use thereof
WO2005105788A1 (en) * 2004-04-23 2005-11-10 Takeda San Diego, Inc. Indole derivatives and use thereof as kinase inhibitors
US7601714B2 (en) 2004-07-08 2009-10-13 Boehringer Ingelheim Pharmaceuticals, Inc. Pyrimidine derivatives useful as inhibitors of PKC-theta
WO2006023931A2 (en) 2004-08-18 2006-03-02 Takeda San Diego, Inc. Kinase inhibitors
EP1812439B2 (de) 2004-10-15 2017-12-06 Takeda Pharmaceutical Company Limited Kinaseinhibitoren
PT1841765E (pt) 2004-12-21 2009-05-14 Gilead Sciences Inc Anticorpos para mcp-1 humano
PE20060776A1 (es) * 2004-12-27 2006-09-26 Boehringer Ingelheim Pharma Mimeticos de glucocorticoides, metodos para prepararlos y composiciones farmaceuticas
BRPI0607062A2 (pt) 2005-02-28 2009-08-04 Japan Tobacco Inc composto de aminopiridina com atividade inibidora de syk, composição farmacêutica e agente terapêutico compreendendo os mesmos
ATE432260T1 (de) * 2005-03-28 2009-06-15 Boehringer Ingelheim Int Pyridinderivate als pkc-theta-hemmer
EA015890B1 (ru) * 2005-06-14 2011-12-30 Тайджен Байотекнолоджи Ко. Лтд. Производные пиримидина
US8193206B2 (en) 2005-06-14 2012-06-05 Taigen Biotechnology Co., Ltd. Pyrimidine compounds
US8119655B2 (en) 2005-10-07 2012-02-21 Takeda Pharmaceutical Company Limited Kinase inhibitors
JP2009521488A (ja) * 2005-12-21 2009-06-04 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング Ｐｋｃ−シータのインヒビターとして有益なピリミジン誘導体
EP1966207A2 (de) * 2005-12-21 2008-09-10 Pfizer Products Inc. Pyrimidinderivate zur behandlung von anormalem zellwachstum
US7754720B2 (en) 2006-07-07 2010-07-13 Gilead Sciences, Inc. Pyridazine compound and use thereof
EP2223925A1 (de) * 2006-10-09 2010-09-01 Takeda Pharmaceutical Company Limited Kinase-Inhibitoren
JP2010505962A (ja) 2006-10-09 2010-02-25 武田薬品工業株式会社 キナーゼ阻害剤
MX2009005264A (es) * 2006-12-06 2009-05-28 Boehringer Ingelheim Int Mimeticos de glucocorticoides, metodos para su fabricacion, composiciones farmaceuticas y usos de los mismos.
US20080242861A1 (en) * 2007-04-02 2008-10-02 Chi-Feng Yen Synthesis of amino-protected cyclohexane-1,4-diyldimethanamine and its derivatives
UA99466C2 (en) 2007-07-06 2012-08-27 Гилиад Сайенсиз, Инк. Crystalline pyridazine compound
CN101903357A (zh) 2007-07-17 2010-12-01 里格尔药品股份有限公司 作为pkc抑制剂的环状胺取代的嘧啶二胺
US8173635B2 (en) * 2007-11-02 2012-05-08 Vertex Pharmaceuticals Incorporated Kinase inhibitors
AU2008355098B2 (en) 2008-04-21 2012-11-15 Gpcr Therapeutics, Inc Heterocyclic compounds
DK2300472T3 (da) * 2008-06-06 2012-04-10 Boehringer Ingelheim Int Glucocorticoidmimetika, fremgangsmåder til disses fremstilling, farmaceutiske sammensætninger samt anvendelser deraf
EP2325175A4 (de) * 2008-09-01 2012-03-21 Astellas Pharma Inc 2,4-diaminopyrimidinverbindung
WO2010056847A2 (en) 2008-11-13 2010-05-20 Taigen Biotechnology Co., Ltd. Lyophilization formulation
KR20120005460A (ko) * 2009-04-28 2012-01-16 베링거 인겔하임 인터내셔날 게엠베하 Ｐｋｃ-세타 억제제를 사용하는 면역학적 장애의 생체외 치료
JP2012148977A (ja) * 2009-05-20 2012-08-09 Astellas Pharma Inc アミノシクロヘキシルアルキル基を有する２，４−ジアミノピリミジン化合物
US20110142814A1 (en) * 2009-12-16 2011-06-16 New York University Methods for Using Protein Kinase C-Theta Inhibitors in Adoptive Immunotherapy
AU2011260323A1 (en) 2010-06-04 2012-11-15 F. Hoffmann-La Roche Ag Aminopyrimidine derivatives as LRRK2 modulators
KR101566091B1 (ko) 2010-11-10 2015-11-04 에프. 호프만-라 로슈 아게 Lrrk2 조절제로서 피라졸 아미노피리미딘 유도체
WO2012080834A1 (en) 2010-12-17 2012-06-21 Rhodes Technologies Low-temperature synthesis of methylphenidate hydrochloride
TWI548621B (zh) * 2011-04-22 2016-09-11 標誌製藥公司 經取代之二胺基甲醯胺及二胺基甲腈嘧啶、其組合物、及以該等治療之方法
AU2016244228B2 (en) * 2011-04-22 2019-02-21 Signal Pharmaceuticals, Llc Substituted diaminocarboxamide and diaminocarbonitrile pyrimidines, compositions thereof, and methods of treatment therewith
GB201108225D0 (en) 2011-05-17 2011-06-29 Amakem Nv Novel KBC inhibitors
EP2864291B1 (de) 2012-06-26 2016-10-05 Bayer Pharma Aktiengesellschaft N-[4-(chinolin-4-yloxy)(cyclohexyl)methyl)] hetero)arylcarboxamide als androgenrezeptorantagonisten, ihre herstellung und verwendung als arzneimittel
CA2923765C (en) 2013-09-18 2021-06-29 University Of Canberra Stem cell modulation ii
RU2016129380A (ru) 2013-12-20 2018-01-25 СИГНАЛ ФАРМАСЬЮТИКАЛЗ, ЭлЭлСи Замещенные диаминопиримидильные соединения, их композиции и способы лечения с их участием
NZ715903A (en) 2014-01-30 2017-06-30 Signal Pharm Llc Solid forms of 2-(tert-butylamino)-4-((1r,3r,4r)-3-hydroxy-4-methylcyclohexylamino)-pyrimidine-5-carboxamide, compositions thereof and methods of their use
AU2015309686B2 (en) 2014-08-25 2020-05-14 Epiaxis Therapeutics Pty Ltd Compositions for modulating cancer stem cells and uses therefor
EP3712134B1 (de) 2014-12-16 2023-11-29 Signal Pharmaceuticals, LLC Salze von 2-(tert-butylamino)-4-((1r, 3r, 4r)-3-hydroxy-4-methycyclohexylamino)-pyrimidin-5-carboxamid
US9513297B2 (en) 2014-12-16 2016-12-06 Signal Pharmaceuticals, Llc Methods for measurement of inhibition of c-Jun N-terminal kinase in skin
EP3250557B1 (de) 2015-01-29 2024-11-20 Signal Pharmaceuticals, LLC Isotopologe von 2-(tert-butylamino)-4-((1r,3r,4r)-3-hydroxy-4-methylcyclohexylamino)-pyrimidin-5-carboxamid
EP3325432B1 (de) 2015-07-24 2020-09-02 Celgene Corporation Verfahren zur synthese von (1r, 2r, 5r)-5-amino-2-methylcyclohexanolhydrochlorid und nützliche zwischenprodukte darin
EP3328496A4 (de) 2015-08-02 2018-12-19 H. Lee Moffitt Cancer Center And Research Institute, Inc. Inhibitoren einer ack1/tnk2.tyrosinkinase
EP3762379A1 (de) 2018-03-07 2021-01-13 Bayer Aktiengesellschaft Identifizierung und verwendung von erk5-inhibitoren
WO2020234103A1 (en) 2019-05-21 2020-11-26 Bayer Aktiengesellschaft Identification and use of kras inhibitors
US20260209211A1 (en) * 2022-12-16 2026-07-23 Adlai Nortye Biopharma Co., Ltd. Cyclin k degrader and use thereof

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9523675D0 (en) 1995-11-20 1996-01-24 Celltech Therapeutics Ltd Chemical compounds
ATE401312T1 (de) * 1997-12-15 2008-08-15 Astellas Pharma Inc Pyrimidin-5-carboxamid-derivate
EP1184376B1 (de) 1999-06-09 2005-02-02 Yamanouchi Pharmaceutical Co. Ltd. Neuartige heterocyclische carboxamid-derivate
EP1206265B1 (de) 1999-06-30 2003-11-12 Merck & Co., Inc. Src-kinase hemmende verbindungen
GB0004887D0 (en) 2000-03-01 2000-04-19 Astrazeneca Uk Ltd Chemical compounds
AU2002258400A1 (en) 2001-02-16 2002-08-28 Tularik Inc. Methods of using pyrimidine-based antiviral agents
IL159120A0 (en) 2001-05-29 2004-05-12 Schering Ag Cdk inhibiting pyrimidines, production thereof and their use as medicaments
GB0113041D0 (en) 2001-05-30 2001-07-18 Astrazeneca Ab Chemical compounds
JP4460292B2 (ja) * 2001-10-17 2010-05-12 ベーリンガー インゲルハイム ファルマ ゲゼルシャフト ミット ベシュレンクテル ハフツング ウント コンパニー コマンディトゲゼルシャフト ピリミジン誘導体、これらの化合物を含む医薬組成物、その使用及びその調製方法
TWI329105B (en) * 2002-02-01 2010-08-21 Rigel Pharmaceuticals Inc 2,4-pyrimidinediamine compounds and their uses
WO2003106451A1 (en) 2002-06-14 2003-12-24 Altana Pharma Ag Substituted diaminopyrimidines
EP1590334B1 (de) 2003-01-30 2009-08-19 Boehringer Ingelheim Pharmaceuticals Inc. 2,4-diaminopyrimidinderivate, die sich als inhibitoren von pkc-theta eignen

Also Published As

Publication number Publication date
US20040242613A1 (en) 2004-12-02
US20050124640A1 (en) 2005-06-09
US7550473B2 (en) 2009-06-23
EP1590334B1 (de) 2009-08-19
CA2514612A1 (en) 2004-08-12
WO2004067516A1 (en) 2004-08-12
JP2006515014A (ja) 2006-05-18
DE602004022633D1 (de) 2009-10-01
EP1590334A1 (de) 2005-11-02

Similar Documents

Publication Publication Date Title
DE602004022633D1 (de) 2,4-diaminopyrimidinderivate, die sich als inhibitoren von pkc-theta eignen
ATE451376T1 (de) Zusammensetzungen, die sich als inhibitoren von proteinkinasen eignen
CY1111070T1 (el) Παραγωγα 2-αμινο-κουιναζολινης χρησιμα ως αναστολεις της β-σεκρετασης (bace)
DE60214703D1 (de) Thiazolverbindungen, die sich als inhibitoren von proteinkinasen eignen
EA200600294A1 (ru) [1,8] нафтиридин-2-оны и родственные соединения для лечения шизофрении
CY1109808T1 (el) Αρυλινδενο-πυριδινες και αρυλινδενο-πυριμιδινες και η χρηση τους ως ανταγωνιστων των υποδοχεων αδενοσινης α2α
NO20030895D0 (no) Ny anvendelse av dipeptidyl peptidase IV inhibitorer
IS7925A (is) Hýdroxýetýlamínafleiður til að meðhöndla Alzheimers-sjúkdóm
MXPA03011484A (es) Heteroarilos multiciclicos sustituidos con quinuclidinas para el tratamiento de enfermedades.
NO20083411L (no) Indaneddiksyrederivater og deres anvendelse som farmasoytiske midler, intermediater og fremgangsmater for fremstilling
CY1111086T1 (el) Παραγωγα 2-αμινο-κιναζολινης χρησιμα ως αναστολεις της βητα-σεκρετασης (bace)
NO20021358L (no) Alkylendiamin-substituerte heterocykler
NO20060230L (no) Nye aminobenzofenonforbindelser
EA200601239A1 (ru) Замещённые хинолиновые соединения
ATE432260T1 (de) Pyridinderivate als pkc-theta-hemmer
NO20073839L (no) Kinolinderivat, fremgangsmate for fremstilling og anvendelse av dette, og legemiddel inneholdende dette
MY141528A (en) Anilinopyrazole derivatives useful for the treatment of diabetes
NO20062256L (no) Hydroksyalkylsubstituerte pyrido-7-pyrimidin-7-oner
DE60308699D1 (en) 2-phenylamino-4-trifluoromethyl-5-(benzyl- oder pyridin-4-ylmethyl)carbamoylpyrimidin-derivate als selektive cb2 cannabinoid-rezeptor modulatoren
WO2006055434A3 (en) Macrocyclic tertiary amine beta-secretase inhibitors for the treatment of alzheimer's disease
ES2333026T3 (es) Derivados de ciclohexil-1,4-diamina sustituidos.
EA200600115A1 (ru) Производные 2-аминобензойной кислоты
ATE383343T1 (de) Imidazolderivate verwendbar als histamin h3 rezeptorliganden
EP1597234A4 (de) Neue verbindungen
BR0112123A (pt) Composto

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties